MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463880 | Name: Lornoxicam-d4
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lornoxicam-d4 is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells, which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells, which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 65 and 54 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg/kg. Formulations containing lornoxicam have been used in the management of postoperative pain.

Chemical Structure

Lornoxicam-d4
Lornoxicam-d4
CAS#1216527-48-8

Theoretical Analysis

MedKoo Cat#: 463880

Name: Lornoxicam-d4

CAS#: 1216527-48-8

Chemical Formula: C13H6D4ClN3O4S2

Exact Mass: 375.0052

Molecular Weight: 375.83

Elemental Analysis: C, 41.55; H, 3.75; Cl, 9.43; N, 11.18; O, 17.03; S, 17.06

Price and Availability

Size Price Availability Quantity
5mg USD 395.00 2 Weeks
10mg USD 700.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Lornoxicam-d4; Lornoxicam d4; Chlortenoxicam-d4; Chlortenoxicam d4; Ro 13-9297-d4; Ro 13-9297 d4;
IUPAC/Chemical Name
6-chloro-4-hydroxy-2-methyl-N-(pyridin-2-yl-d4)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
InChi Key
WLHQHAUOOXYABV-QFFDRWTDSA-N
InChi Code
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)/i2D,3D,4D,5D
SMILES Code
OC(C1=C2C=C(Cl)S1)=C(N(S2(=O)=O)C)C(NC3=C(C([2H])=C(C([2H])=N3)[2H])[2H])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Lornoxicam (Chlortenoxicam), a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID).
In vitro activity:
In intact human cells, lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested. NO formation was dose-dependently inhibited by lornoxicam (IC50 of 65 microM) whereas piroxicam, diclofenac, ibuprofen, ketorolac and naproxen inhibited the NO formation markedly less. Reference: Inflamm Res. 1999 Jul;48(7):369-79. https://pubmed.ncbi.nlm.nih.gov/10450786/
In vivo activity:
A corneal latent herpes simplex virus-1 (HSV-1) infected mouse model was established. Six weeks later, Ultraviolet B (UVB) irradiation induced the recurrence. Lornoxicam treatment significantly decreased the incidence of recurrent HSK, attenuated the corneal opacity scores, and also effectively suppressed both NF-kappaB activation and TNF-alpha expression in biological analysis. Reference: Mol Vis. 2009 Jun 14;15:1252-9. https://pubmed.ncbi.nlm.nih.gov/19547717/
Solvent mg/mL mM
Solubility
DMSO 2.0 5.32
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 375.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hussen J, Kandeel M, Shawaf T, Al-Mubarak AIA, Al-Humam NA, Almathen F. Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes. Animals (Basel). 2021 Jul 6;11(7):2023. doi: 10.3390/ani11072023. PMID: 34359151; PMCID: PMC8300418. 2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474. PMID: 10450786. 3. Yin J, Huang Z, Xia Y, Ma F, Zhang LJ, Ma HH, Li Wang L. Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice. Mol Vis. 2009 Jun 14;15:1252-9. PMID: 19547717; PMCID: PMC2697669.
In vitro protocol:
1. Hussen J, Kandeel M, Shawaf T, Al-Mubarak AIA, Al-Humam NA, Almathen F. Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes. Animals (Basel). 2021 Jul 6;11(7):2023. doi: 10.3390/ani11072023. PMID: 34359151; PMCID: PMC8300418. 2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474. PMID: 10450786.
In vivo protocol:
1. Yin J, Huang Z, Xia Y, Ma F, Zhang LJ, Ma HH, Li Wang L. Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice. Mol Vis. 2009 Jun 14;15:1252-9. PMID: 19547717; PMCID: PMC2697669.
1: Lin L, Xu L, Kuang H, Xiao J, Xu C. Ultrasensitive and simultaneous detection of 6 nonsteroidal anti-inflammatory drugs by colloidal gold strip sensor. J Dairy Sci. 2021 Jan 14:S0022-0302(21)00058-8. doi: 10.3168/jds.2020-19500. Epub ahead of print. PMID: 33455779. 2: Fang D, Yang Y, Cui M, Pan H, Wang L, Li P, Wu W, Qiao S, Pan W. Three- Dimensional (3D)-Printed Zero-Order Released Platform: a Novel Method of Personalized Dosage Form Design and Manufacturing. AAPS PharmSciTech. 2021 Jan 6;22(1):37. doi: 10.1208/s12249-020-01886-8. PMID: 33409925. 3: Ahmed S, Kassem MA, Sayed S. Bilosomes as Promising Nanovesicular Carriers for Improved Transdermal Delivery: Construction, in vitro Optimization, ex vivo Permeation and in vivo Evaluation. Int J Nanomedicine. 2020 Dec 8;15:9783-9798. doi: 10.2147/IJN.S278688. PMID: 33324052; PMCID: PMC7733410. 4: Karakitsou V, Adamama-Moraitou K, Papazoglou LG, Kazakos G, Timiou D, Polydoros T, Tahmazidou A, Mylonakis ME. Presumptive Lornoxicam Intoxication in Four Dogs. Top Companion Anim Med. 2020 Nov 26;42:100502. doi: 10.1016/j.tcam.2020.100502. Epub ahead of print. PMID: 33249243. 5: Prajapati P, Radadiya V, Shah S. Failure Mode Critical Effect Analysis and Design of Experiment-Based Robust Chromatographic Method for Simultaneous Estimation Lornoxicam and Eperisone Hydrochloride. J Chromatogr Sci. 2020 Oct 26;58(10):929-939. doi: 10.1093/chromsci/bmaa064. PMID: 32887996. 6: He Y, Majid K, Maqbool M, Hussain T, Yousaf AM, Khan IU, Mehmood Y, Aleem A, Arshad MS, Younus A, Nirwan JS, Ghori MU, Rizvi SAA, Shahzad Y. Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel for possible applications in arthritis. Saudi Pharm J. 2020 Aug;28(8):994-1003. doi: 10.1016/j.jsps.2020.06.021. Epub 2020 Jul 3. PMID: 32792844; PMCID: PMC7414098. 7: Cao J, Gao X, Zhang X, Li J, Zhang J. Feasibility of laryngeal mask anesthesia combined with nerve block in adult patients undergoing internal fixation of rib fractures: a prospective observational study. BMC Anesthesiol. 2020 Jul 15;20(1):170. doi: 10.1186/s12871-020-01082-y. PMID: 32669087; PMCID: PMC7362641. 8: Popov VV, Gildeeva GN, Butuzova DV, Ezhova EA, Belostotskiy AV, Bulanova NA. Issledovanie effektivnosti i bezopasnosti vosproizvedennogo preparata lornoksikam u patsientov s ostroi lyumboishialgiei [A study of the efficacy and safety of lornoxicam in patients with acute sciatica]. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(5):42-49. Russian. doi: 10.17116/jnevro202012005142. PMID: 32621467. 9: Anumolu PD, Gurrala S, Gellaboina A, Mangipudi DG, Menkana S, Chakka R. Spectrophotometric Quantification of Anti-inflammatory Drugs by Application of Chromogenic Reagents. Turk J Pharm Sci. 2019 Dec;16(4):410-415. doi: 10.4274/tjps.galenos.2018.07830. Epub 2019 Nov 11. PMID: 32454743; PMCID: PMC7227883. 10: Hashmat D, Shoaib MH, Ali FR, Siddiqui F. Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co- solvents as penetration enhancers. PLoS One. 2020 Feb 27;15(2):e0228908. doi: 10.1371/journal.pone.0228908. PMID: 32107483; PMCID: PMC7046209. 11: Gromova OA, Torshin IY, Putilina MV, Stakhovskaia LV, Rudakov KV. Khemoreaktomnyĭ analiz tsentral'nykh mekhanizmov nesteroidnykh protivovospalitel'nykh preparatov [The chemoreactomic analysis of the central mechanisms of action of non-steroidal anti-inflammatory drugs]. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(1):70-77. Russian. doi: 10.17116/jnevro202012001170. PMID: 32105272. 12: Oros M, Oros Jar M, Grabar V. Steroids and L-Lysine Aescinate for Acute Radiculopathy Due to a Herniated Lumbar Disk. Medicina (Kaunas). 2019 Nov 14;55(11):736. doi: 10.3390/medicina55110736. PMID: 31739434; PMCID: PMC6915681. 13: Martinez L, Ekman E, Nakhla N. Perioperative Opioid-sparing Strategies: Utility of Conventional NSAIDs in Adults. Clin Ther. 2019 Dec;41(12):2612-2628. doi: 10.1016/j.clinthera.2019.10.002. Epub 2019 Nov 14. PMID: 31733939. 14: Ma Y, Yu P, Lin S, Li Q, Fang Z, Huang Z. The association between nonsteroidal anti-inflammatory drugs and skin cancer: Different responses in American and European populations. Pharmacol Res. 2020 Feb;152:104499. doi: 10.1016/j.phrs.2019.104499. Epub 2019 Nov 2. PMID: 31689521. 15: Coşkun E, Dinçer E, Turan G, Özgültekin A. Postoperative Analgesic Efficacy of Preemptive and Postoperative Lornoxicam or Tramadol in Lumbar Disc Surgery. Turk J Anaesthesiol Reanim. 2019 Oct;47(5):375-381. doi: 10.5152/TJAR.2019.60963. Epub 2019 May 20. PMID: 31572987; PMCID: PMC6756307. 16: Gao S, Tian B, Han J, Zhang J, Shi Y, Lv Q, Li K. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema. Int J Nanomedicine. 2019 Aug 2;14:6135-6150. doi: 10.2147/IJN.S205295. PMID: 31447556; PMCID: PMC6683961. 17: Salunkhe N, Jadhav N, More H, Choudhari P. Sericin Inhibits Devitrification of Amorphous Drugs. AAPS PharmSciTech. 2019 Aug 12;20(7):285. doi: 10.1208/s12249-019-1475-z. PMID: 31407105. 18: Tolska HK, Hamunen K, Takala A, Kontinen VK. Systematic review of analgesics and dexamethasone for post-tonsillectomy pain in adults. Br J Anaesth. 2019 Aug;123(2):e397-e411. doi: 10.1016/j.bja.2019.04.063. Epub 2019 Jun 17. PMID: 31221427; PMCID: PMC6676167. 19: Jalalifar S. Cyclooxygenases inhibitors for preventing the proliferative vitreoretinopathy: Ready for clinical use? Arch Soc Esp Oftalmol. 2019 Sep;94(9):e63-e64. English, Spanish. doi: 10.1016/j.oftal.2019.04.010. Epub 2019 Jun 8. PMID: 31182242. 20: Naumov AV, Tkacheva ON, Khovasova NO. Safety of nonsteroidal anti- inflammatory drugs in patients with cardiovascular risk. Ter Arkh. 2019 Mar 11;91(1):108-113. doi: 10.26442/00403660.2019.01.000039. PMID: 31090381.

View History

CB 3731

CB 3731